US EditionSCAI 2025: SAPT after TAVI should be considered “standard of care” - Cardiovascular News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
SCAI 2025: SAPT after TAVI should be considered “standard of care” - Cardiovascular News
Single antiplatelet therapy (SAPT) after transcatheter aortic valve implantation (TAVI) is associated with a significantly lower incidence of six-month mortality and major bleeding risk compared to dual antiplatelet therapy (DAPT). This is the finding of the Transfusion requirements in transcatheter aortic valve implantation—TRITAVI—registry, presented during a late-breaking trial session by Francesco Pelliccia (Sapienza University, Rome, Italy)…
Analysis From TRITAVI Registry Compares SAPT and DAPT After TAVR - Cardiac Interventions Today
May 1, 2025—The Society for Cardiovascular Angiography & Interventions (SCAI) announced that findings from an analysis of the Transfusion Requirements in Transcatheter Aortic Valve Implantation (TRITAVI) registry demonstrated that single antiplatelet therapy (SAPT) after transcatheter aortic valve replacement (TAVR) is associated with a significantly lower incidence of 6-month mortality and major bleeding risk compared to dual antiplatelet thera…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
